Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SNDX
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
SNDX
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

SNDX Similar Chart Price Prediction

The price of SNDX is predicted to go up -1.48%, based on the high correlation periods with ALNY. The similarity of these two price pattern on the periods is 93.75%.

stocks logo

SNDX

stocks logo

ALNY

Down: -1.48%Similarity: 93.75%

SNDX Revenue Forecast

SNDX EPS Forecast

SNDX FAQs

What is bull’s view on SNDX?

SNDX stock is currently trading at $14.16. The bull's view is driven by recent FDA approval of Niktimvo for chronic GVHD, with expected U.S. availability in early February, which could boost revenue. Analysts like Citigroup have a strong buy rating with a price target of $45, indicating a potential upside of over 200%.

What is bear's view on SNDX?

SNDX stock faces bearish sentiment due to a recent price target cut by Scotiabank from $18 to $16, reflecting concerns about limited near-term upside. Despite FDA approval for Niktimvo, the stock's current price of $13.80 (as of the last close) suggests skepticism about immediate revenue impact. Additionally, broader market conditions and competition in the biotech sector weigh on its valuation.

What is SNDX revenue forecast for next quarter？

The market consensus for SNDX's revenue in the upcoming quarter is projected to be approximately $14.701M USD.

What is SNDX eps forecast for next quarter？

The market consensus for SNDX's eps in the upcoming quarter is projected to be approximately $1.10 USD.

SNDX VS S&P500

Ask Intellectia about SNDX

SNDX Analyst's Forecast

Yigal Nochomovitz

Citigroup

Strong Buy

Price Target

$37 → $45

Upside

+185.35%

Citi raised the firm's price target on Syndax to $45 from $37 and keeps a Buy rating on the shares after the FDA granted approval for Revuforj. The "early green-light highlights that concerns" around the three-month extension were unfounded, the analyst tells investors in a research note. The firm says Revuforj's boxed warning for differentiation syndrome is likely to be implemented across the broader menin-inhibtior class and does not represent a competitive disadvantage.
David Dai

UBS

Strong Buy

Price Target

$37

Upside

+94.84%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free